In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewAdvances in epigenetic glioblastoma therapy.Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.Romidepsin for the treatment of non-Hodgkin's lymphoma.Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.Inhibition of HDAC6 activity through interaction with RanBPM and its associated CTLH complex.TDP-43/HDAC6 axis promoted tumor progression and regulated nutrient deprivation-induced autophagy in glioblastoma.The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphomaChanges in cardiac Nav1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors.HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.Counteracting survival functions of EBNA3C in Epstein-Barr virus (EBV)-driven lymphoproliferative diseases by combination of SAHA and bortezomib.Histone deacetylase 6 in cancerThe Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
P2860
Q27304386-9AA53A12-C38F-41C7-88F7-0084838A38ACQ33567030-A154139C-5EB7-4675-943F-85190908DC0DQ35764582-557522DA-9D30-421B-97D4-4A0CA0580FABQ36301520-BBBD2AB3-208C-457E-8D21-0D5DD3BB2D53Q36578084-C72EA4C6-977E-4747-963A-BA54DFF0115BQ37301751-06EF68B6-A0EA-40B8-A59B-B0C3D791CBFFQ38455740-A0CB676F-554B-4719-B3EB-977F1A8247B5Q38896751-B8B889C0-85B8-46C6-A56D-F1549EEFA9C9Q39153404-BDDB1D9D-E1CB-4C6F-93EC-850FCEC304D6Q41345579-C8589D51-91AD-4944-8AF6-8320CC1B64B2Q42070740-9B0F3B00-9693-486A-AD46-B9F0EA5FE7B2Q42784091-897914EC-CE9C-42EB-96E1-BBAD03BEBA30Q48601823-2CDE0EC4-DEC3-4D0F-B487-ACA7D0FC1C20Q50147664-6DF11F4B-9FF7-4B40-BA20-CFCDA2C2E3ECQ55221402-3E1EED4E-92A6-4D5C-867F-C8D091268184Q58768571-8BD3CFAD-6F57-4EBF-93A6-C9497E326BEEQ58792448-9EC7C464-68FF-4086-A732-C9F36743CAE7
P2860
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
In vitro and in vivo interacti ...... in non-Hodgkin lymphoma cells
@ast
In vitro and in vivo interacti ...... in non-Hodgkin lymphoma cells
@en
type
label
In vitro and in vivo interacti ...... in non-Hodgkin lymphoma cells
@ast
In vitro and in vivo interacti ...... in non-Hodgkin lymphoma cells
@en
prefLabel
In vitro and in vivo interacti ...... in non-Hodgkin lymphoma cells
@ast
In vitro and in vivo interacti ...... in non-Hodgkin lymphoma cells
@en
P2093
P2860
P1476
In vitro and in vivo interacti ...... in non-Hodgkin lymphoma cells
@en
P2093
Girija Dasmahapatra
Hiral Patel
Johnathan Friedberg
Simon S Jones
Steven Grant
Steven N Quayle
P2860
P304
P356
10.1158/1535-7163.MCT-14-0220
P577
2014-09-19T00:00:00Z